Intrexon | XON - Assets


Intrexon reported $73.16M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
Agenus USD 226.8M 7.09M Dec/2025
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
Amgen USD 90.59B 445M Dec/2025
Anika Therapeutics USD 190.27M 833K Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
MannKind USD 792.18M 297.54M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 110.95B 3.66B Dec/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 110.34B 7.32B Dec/2025
Veracyte USD 1.41B 38.23M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025